Charles River Laboratories

CRL

Market cap $8.67B

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Overall, the best strategy for these stocks is to buy all or almost all of them. Buying just one or two means taking on more single-stock risk.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with the American Heart Association, the world's leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives. “New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities,” said Kristen Eisenhau.

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 6, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at TD Cowen and Barclays Conferences.

Contract drug developer Charles River Laboratories raised its 2026 profit forecast on Wednesday, after it announced the sales of some underperforming assets to peer IQVIA and private equity firm GI Partners.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Update on Planned Divestitures.